原发性硬化性胆管炎临床试验的设计与终点
Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis.
PubMed 文献 · Hepatology · 2018-08-31
本文综述了监管信息、自然史文献以及原发性硬化性胆管炎(PSC)候选临床和替代终点,指出该病为罕见慢性肝病且尚无有效治疗,目前缺乏衡量临床获益的明确方法。
要点
- PSC为罕见慢性肝病,目前尚无有效治疗。
- 多种药物被提议作为PSC的潜在治疗,但临床试验中如何衡量临床获益尚不明确。
- 本文综述监管信息、自然史文献及候选临床与替代终点。
核心结论
- PSC为罕见慢性肝病且尚无有效治疗,临床试验中衡量临床获益的方法尚不明确。
研究设计与样本
- 综述,检索范围包括监管信息、自然史文献以及PSC候选临床和替代终点。
主要发现
- 多种药物被提议作为PSC的潜在治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary sclerosing cholangitis (PSC) is a rare and chronic liver disease for which there is no effective therapy. Interest has grown in developing treatments for this condition, with several agents proposed as potential therapies. However, there is a lack of clarity about how to measure clinical benefit in trials involving patients with this complex and rare disease. This article reviews regulatory information, the available literature on natural history, as well as potential candidate clinical and surrogate endpoints for PSC. (Hepatology 2018; 00:000-000).
来源:Hepatology,查看原文。版权归原作者所有。
引用
- Ponsioen CY, Lindor KD, Mehta R, et al. Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis. Hepatology. 2018. PMID: 29574971. doi:10.1002/hep.29882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。